OpGen is a medical devices business based in the US. OpGen shares (OPGN) are listed on the NASDAQ and all prices are listed in US Dollars. OpGen employs 85 staff and has a trailing 12-month revenue of around $2.8 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.23 |
|---|---|
| 52-week range | $0.17 - $8.96 |
| 50-day moving average | $0.41 |
| 200-day moving average | $1.20 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-12.89 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.229 from 2023-09-22
| 1 week (2023-09-15) | 0.44% |
|---|---|
| 1 month (2023-08-24) | 28.65% |
| 3 months (2023-06-23) | -63.65% |
| 6 months (2023-03-23) | -83.64% |
| 1 year (2022-09-23) | -40.86% |
|---|---|
| 2 years (2021-09-24) | -92.49% |
| 3 years (2020-09-24) | 2.07 |
| 5 years (2018-09-24) | 44 |
| Revenue TTM | $2.8 million |
|---|---|
| Gross profit TTM | $-8,990,133 |
| Return on assets TTM | -37.42% |
| Return on equity TTM | -211.58% |
| Profit margin | 0% |
| Book value | $0.99 |
| Market Capitalization | $2 million |
TTM: trailing 12 months
We're not expecting OpGen to pay a dividend over the next 12 months.
OpGen's shares were split on a 1:20 basis on 4 January 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OpGen shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OpGen shares which in turn could have impacted OpGen's share price.
Over the last 12 months, OpGen's shares have ranged in value from as little as $0.165 up to $8.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OpGen's is -0.1404. This would suggest that OpGen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, OpGen has bucked the trend.
OpGen, Inc. , a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.